1. Home
  2. MASS vs NYXH Comparison

MASS vs NYXH Comparison

Compare MASS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 908 Devices Inc.

MASS

908 Devices Inc.

N/A

Current Price

$6.03

Market Cap

241.4M

Sector

Health Care

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$3.46

Market Cap

190.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MASS
NYXH
Founded
2012
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.4M
190.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MASS
NYXH
Price
$6.03
$3.46
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$12.00
$11.67
AVG Volume (30 Days)
248.0K
55.1K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
125.47
N/A
EPS
0.54
N/A
Revenue
$56,197,000.00
N/A
Revenue This Year
$18.58
$97.32
Revenue Next Year
$15.12
$241.74
P/E Ratio
$14.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.55
$3.39
52 Week High
$9.34
$11.87

Technical Indicators

Market Signals
Indicator
MASS
NYXH
Relative Strength Index (RSI) 40.73 32.41
Support Level $5.26 N/A
Resistance Level $6.06 $5.02
Average True Range (ATR) 0.49 0.26
MACD -0.09 -0.07
Stochastic Oscillator 5.03 4.18

Price Performance

Historical Comparison
MASS
NYXH

About MASS 908 Devices Inc.

908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: